1. Scrip
  2. >>Business

Pharma On The Hunt For Oncology Partners Across Modalities

For Novel Targets, New Approaches To Known Targets

 
• By Mandy Jackson

The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.

Tumor microenvironment concept with cancer cells, T-Cells, nanoparticles, cancer associated fibroblast layer of tumor microenvironment
Pharma firms expressed interest in new drug candidates, platforms and other technologies • Source: Shutterstock

Figuring out how to get a foot in the door with potential big pharma partners is a daunting task for academic researchers and small biotechnology companies. The organizers of the inaugural American Association of Cancer Research (AACR) Oncology Industry Partnering Event hope the two-day meeting will help academics and biotech executives take their first steps toward pharma firms hungry for the next big ideas in cancer drug development.

Key Takeaways

  • Big pharma companies gave potential academic and biotech collaborators a look at their cancer R&D and dealmaking strategies during the inaugural AACR Oncology Industry Partnering Event.

Twelve big pharma companies descended on San Diego for the partnering event on 4-5 April, just ahead of AACR’s annual...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.